Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Serial determination of FLT3 mutations in myelodysplastic syndrome patients at diagnosis, follow up or acute myeloid leukaemia transformation: incidence and their prognostic significance.
Georgiou G, Karali V, Zouvelou C, Kyriakou E, Dimou M, Chrisochoou S, Greka P, Dufexis D, Vervesou E, Dimitriadou E, Efthymiou A, Petrikkos L, Dima K, Lilakos K, Panayiotidis P. Georgiou G, et al. Among authors: efthymiou a. Br J Haematol. 2006 Aug;134(3):302-6. doi: 10.1111/j.1365-2141.2006.06171.x. Epub 2006 Jun 20. Br J Haematol. 2006. PMID: 16787503 Free article.
Clonotypic analysis of immunoglobulin heavy chain sequences in patients with Waldenström's macroglobulinemia: correlation with MYD88 L265P somatic mutation status, clinical features, and outcome.
Petrikkos L, Kyrtsonis MC, Roumelioti M, Georgiou G, Efthymiou A, Tzenou T, Panayiotidis P. Petrikkos L, et al. Among authors: efthymiou a. Biomed Res Int. 2014;2014:809103. doi: 10.1155/2014/809103. Epub 2014 Aug 14. Biomed Res Int. 2014. PMID: 25197661 Free PMC article.
Prognostic significance of serum free light chains in chronic lymphocytic leukemia.
Sarris K, Maltezas D, Koulieris E, Bartzis V, Tzenou T, Sachanas S, Nikolaou E, Efthymiou A, Bitsani K, Dimou M, Vassilakopoulos TP, Siakantaris M, Angelopoulou MK, Kontopidou F, Tsaftaridis P, Kafasi N, Pangalis GA, Panayiotidis PP, Harding S, Kyrtsonis MC. Sarris K, et al. Among authors: efthymiou a. Adv Hematol. 2013;2013:359071. doi: 10.1155/2013/359071. Epub 2013 Oct 29. Adv Hematol. 2013. PMID: 24288537 Free PMC article.
Development of acute myeloid leukemia with NPM1 mutation, in Ph-negative clone, during treatment of CML with imatinib.
Georgiou G, Efthymiou A, Vardounioti I, Boutsikas G, Angelopoulou MK, Vassilakopoulos TP, Kyrtsonis MC, Plata E, Tofas P, Bitsani A, Bartzi V, Pessach I, Dimou M, Panayiotidis P. Georgiou G, et al. Among authors: efthymiou a. Leukemia. 2012 Apr;26(4):824-6. doi: 10.1038/leu.2011.280. Epub 2011 Oct 11. Leukemia. 2012. PMID: 21986839 No abstract available.
Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013.
Schnegg-Kaufmann A, Feller A, Baldomero H, Rovo A, Manz MG, Gregor M, Efthymiou A, Bargetzi M, Hess U, Spertini O, Chalandon Y, Passweg JR, Stussi G, Arndt V, Bonadies N; NICER Working Group. Schnegg-Kaufmann A, et al. Among authors: efthymiou a. Cancer Epidemiol. 2018 Feb;52:55-62. doi: 10.1016/j.canep.2017.11.008. Epub 2017 Dec 7. Cancer Epidemiol. 2018. PMID: 29223104
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.
Janssen JJWM, Löwenberg B, Manz M, Biemond BJ, Westerweel PE, Klein SK, Fehr M, Sinnige HAM, Efthymiou A, Legdeur MCJC, Pabst T, Gregor M, van der Poel MWM, Deeren D, Tick LW, Jongen-Lavrencic M, van Obbergh F, Boersma RS, de Weerdt O, Chalandon Y, Heim D, Spertini O, van Sluis G, Graux C, Stüssi G, van Norden Y, Ossenkoppele GJ. Janssen JJWM, et al. Among authors: efthymiou a. Leukemia. 2022 Sep;36(9):2189-2195. doi: 10.1038/s41375-022-01657-3. Epub 2022 Jul 22. Leukemia. 2022. PMID: 35869267 Clinical Trial.
Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS.
Janssen J, Löwenberg B, Manz M, Bargetzi M, Biemond B, Borne PVD, Breems D, Brouwer R, Chalandon Y, Deeren D, Efthymiou A, Gjertsen BT, Graux C, Gregor M, Heim D, Hess U, Hoogendoorn M, Jaspers A, Jie A, Jongen-Lavrencic M, Klein S, Klift MV, Kuball J, Lammeren-Venema DV, Legdeur MC, Loosdrecht AV, Maertens J, Kooy MVM, Moors I, Nijziel M, Obbergh FV, Oosterveld M, Pabst T, Poel MV, Sinnige H, Spertini O, Terpstra W, Tick L, Velden WV, Vekemans MC, Vellenga E, Weerdt O, Westerweel P, Stüssi G, Norden YV, Ossenkoppele G. Janssen J, et al. Among authors: efthymiou a. Cancers (Basel). 2021 Feb 7;13(4):672. doi: 10.3390/cancers13040672. Cancers (Basel). 2021. PMID: 33562393 Free PMC article.
Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)-Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q).
Rüfer A, Angermann H, Benz R, Bonadies N, Calderoni A, Cantoni N, Efthymiou A, Escher R, Favre G, Friess D, Gschwend A, Himmelmann A, Holbro A, Keller P, Kouroupi E, Lehmann T, Pedarnig N, Rigamonti V, Samii K, Schmidt A, Schäfer HP, Sperb R, Stüssi G, Winkler A, Zenhäusern R, Goede JS. Rüfer A, et al. Among authors: efthymiou a. Hemasphere. 2022 Jun 17;6(7):e741. doi: 10.1097/HS9.0000000000000741. eCollection 2022 Jul. Hemasphere. 2022. PMID: 35747588 Free PMC article. No abstract available.
83 results